ArticleIndian journal of surgical oncology2026
Patient-Reported Outcome After Extended Total Mesorectal Excision for Locally Advanced Rectal Cancer in Male Patients.
Article in Indian journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study looks at sexual and urinary dysfunction and quality of life in male patients undergoing extended total mesorectal excision. This cross-sectional study used International Prostatic Symptom Score (IPSS) and the International Index of Erectile Function Score (IIEF) questionnaire-based retrospective analysis of male patients who underwent extended total mesorectal excision from 2015 to 2022. Quality of life was assessed using EORTC QLQ C-30 and EORTC QLQ CR-29. Sixty-eight male patients were included, with a median age of 44 years. Urinary retention and incontinence occurred in 10.3% of patients, and 2 required lifelong catheterization. Nineteen percent and 49% patients had severe urinary and sexual dysfunction as per IPSS and IIEF scores. As per the EORTC C-30 QOL analysis, participants scored a global health status mean score of 33.3 with a standard deviation of 10.76. The highest functional scale score was for cognitive functioning: 78.7 ± 18.67. The symptom scale ranged from 9.30 ± 13.26 for nausea and vomiting to 44.19 ± 27.9 for financial difficulties. According to the EORTC CR 29, impotence (43.41 ± 55.17) and problems with stoma care (37.20 ± 22) scored highest. On the function scale, anxiety about future health (62.79 ± 24.35), interest in sex (65.11 ± 45.4), and body image (65.12 ± 16) scored lowest in this order. The patient had significant urinary and sexual symptoms, resulting in concern about weight, loss of interest in sex, and anxiety about future health. In a high-volume , eTME is not without urinary and sexual dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.